Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing

Featuring an interview with Dr Alexander E Drilon, including the following topics:
Overview of targetable biomarkers in lung cancer (0:00)
Biomarker testing for genomic alterations in lung cancer (5:24)
Overview of ROS1 alterations in lung cancer (13:44)
Efficacy data with ROS1 inhibitors for lung cancer (17:02)
Safety data with ROS1 inhibitors for lung cancer (21:15)
Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)
Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)
Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)

NCPD information and select publications

Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:
Introduction (0:00)
Overview of Prostate Cancer (3:00)
Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)
Potential Role of Capivasertib in Metastatic HSPC (27:22)
Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)
Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)

CME information and select publications

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics:
Introduction (0:00)
Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29)
Recent Advances in Up-Front Treatment for Metastatic PAD (15:47)
Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58)
Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20)
Utility of Tumor Treating Fields in PAD Management (1:13:58)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:
Introduction (0:00)
Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
Practical Considerations with Oral SERDs (15:42)
Potential Role of Combination Approaches with Oral SERDs (26:31)
Gastrointestinal Adverse Events Documented with Oral SERDs (38:17)
Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51)
Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53)
Emerging Utility of Adjuvant Oral SERDs (1:10:16)
Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17)

CME information and select publications

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:
Introduction (00:00)
Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
Strategies to Prevent and Manage Hyperglycemia (27:02)
Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
Mitigation and Management of Gastrointestinal Adverse Events (51:05)
Management of Dermatologic Adverse Events (59:58)
Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
Monitoring and Management of Cytopenias (1:21:23)

CME information and select publications